Actos (Pioglitazone) Cost vs. Alternatives in Class

What Does Pioglitazone Cost Without Insurance?

Generic pioglitazone is one of the most affordable branded-to-generic diabetes drugs on the U.S. market. A 30-day supply of pioglitazone 15 mg or 30 mg tablets typically runs between $4 and $15 at Walmart, Costco, and most grocery-chain pharmacies. The 45 mg strength can reach $25 to $30 per month, though prescribers rarely start patients above 30 mg.

Brand-name Actos, manufactured by Takeda, carried a wholesale acquisition cost above $400 per month before patent expiration in August 2012. Generic entry collapsed the price by roughly 95% within two years [4]. Today, fewer than 1% of pioglitazone prescriptions are filled as brand Actos per IQVIA dispensing data.

Several pharmacy discount programs (GoodRx, RxSaver, Mark Cuban Cost Plus Drugs) list pioglitazone 30 mg at $3.50 to $8.00 for a 30-day supply without any insurance. Cost Plus Drugs prices pioglitazone at a flat manufacturer cost plus 15% markup plus a $5 dispensing fee, which lands near $5 total. This price point puts pioglitazone in the same tier as metformin and glipizide among the cheapest diabetes medications available.

For patients paying out of pocket, pioglitazone is roughly 50 to 100 times cheaper per month than branded SGLT2 inhibitors or GLP-1 receptor agonists. That ratio matters for uninsured patients and in health systems outside the U.S., where formulary decisions weigh cost-effectiveness differently than in commercially insured populations.

How Does Pioglitazone Compare to Metformin on Cost?

Both drugs sit at the bottom of the diabetes cost curve. Metformin 500 mg to 2,000 mg daily costs $4 to $10 per month at retail. Pioglitazone 15 mg to 30 mg daily costs $4 to $15. Neither drug requires prior authorization from most commercial or Medicare Part D plans.

The clinical comparison is less symmetric. The American Diabetes Association (ADA) Standards of Care position metformin as the preferred first-line oral agent for type 2 diabetes, based on decades of outcomes data, weight neutrality relative to TZDs, and gastrointestinal tolerability [5]. Pioglitazone is listed as a second-line or add-on option.

Where pioglitazone separates itself is in insulin sensitization. Metformin reduces hepatic glucose output primarily through AMPK activation. Pioglitazone activates PPARgamma receptors in adipose tissue, redistributing visceral fat to subcutaneous depots and improving skeletal muscle glucose uptake [4]. Dr. Ralph DeFronzo of the University of Texas Health Science Center, who led the ACT NOW prevention trial, has stated: "Pioglitazone is the most potent insulin sensitizer we have. No other oral agent addresses the root pathophysiology of type 2 diabetes as directly" [7].

In the ACT NOW trial (N=602), pioglitazone reduced conversion from impaired glucose tolerance to type 2 diabetes by 72% over a median 2.4 years compared to placebo [7]. Metformin achieved a 31% reduction in the Diabetes Prevention Program. On a per-dollar basis, pioglitazone delivers insulin-sensitizing efficacy that no other comparably priced medication matches.

Pioglitazone vs. Rosiglitazone: Price and Safety

Rosiglitazone (Avandia) is the other FDA-approved thiazolidinedione. It costs $30 to $80 per month as a generic, roughly 3 to 5 times more than pioglitazone. Prescribing volume for rosiglitazone dropped by over 90% after a 2007 meta-analysis by Nissen and Wolski (N=42 trials, 27,847 patients) reported a 43% relative increase in myocardial infarction risk with rosiglitazone versus comparators [8].

The FDA restricted rosiglitazone access from 2010 to 2013, then lifted restrictions after the RECORD trial's final adjudication showed no statistically significant increase in cardiovascular mortality. Prescribing never recovered. Fewer than 50,000 rosiglitazone prescriptions were dispensed in the U.S. in 2024, compared to over 5 million for pioglitazone.

Pioglitazone carries a more favorable cardiovascular signal. The PROactive trial (N=5,238) randomized patients with type 2 diabetes and macrovascular disease to pioglitazone 45 mg or placebo. The primary composite endpoint did not reach significance (HR 0.90, P=0.095), but the pre-specified main secondary endpoint of all-cause mortality, non-fatal MI, and stroke showed a 16% relative risk reduction (HR 0.84, P=0.027) [2]. The later IRIS trial (N=3,876) demonstrated that pioglitazone reduced recurrent stroke or MI by 24% in insulin-resistant patients without diabetes (HR 0.76, 95% CI 0.62 to 0.93) [3].

On both cost and cardiovascular safety, pioglitazone is the preferred TZD. Most formularies have dropped rosiglitazone entirely.

How Pioglitazone Stacks Up Against SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) cost $500 to $650 per month without insurance. With commercial copay cards, patients may pay $0 to $25. Medicare Part D enrollees face donut-hole exposure that can push monthly out-of-pocket costs above $100 during coverage gap periods.

SGLT2 inhibitors have accumulated cardiovascular and renal outcome data that pioglitazone cannot match. EMPA-REG OUTCOME (N=7,020) showed empagliflozin reduced cardiovascular death by 38% in patients with established atherosclerotic disease. DAPA-CKD demonstrated dapagliflozin slowed chronic kidney disease progression regardless of diabetes status. The ADA now recommends SGLT2 inhibitors as preferred add-on therapy for patients with heart failure, CKD, or established ASCVD [5].

Pioglitazone does not have a kidney-protective indication. It causes fluid retention and is contraindicated in NYHA class III/IV heart failure [4]. These limitations narrow its use in the populations where SGLT2 inhibitors shine.

The trade-off is price. For a patient with type 2 diabetes, moderate insulin resistance, and no heart failure or CKD, pioglitazone at $8 per month achieves an A1C reduction of 1.0% to 1.5%, comparable to SGLT2 inhibitors. If insurance coverage is poor or absent, pioglitazone becomes a rational second-line choice purely on affordability. The clinical question is whether the patient's cardiorenal risk profile justifies the 50-fold cost difference.

Pioglitazone vs. GLP-1 Receptor Agonists

GLP-1 receptor agonists represent the most expensive comparator class. Semaglutide (Ozempic) lists at approximately $935 per month. Tirzepatide (Mounjaro) lists near $1,023 per month. Dulaglutide (Trulicity) runs about $900. Even with manufacturer coupons, commercially insured patients typically pay $25 to $150 per month, and uninsured patients face the full list price.

GLP-1 agonists produce greater A1C lowering (1.5% to 2.0%) and weight loss (5% to 15% of body weight) than pioglitazone, which tends to cause weight gain of 2 to 4 kg over 6 to 12 months [4]. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% versus placebo. SELECT (N=17,604) extended this benefit to patients with obesity but without diabetes.

Pioglitazone cannot compete on weight outcomes. It can compete on cost and on one specific indication: non-alcoholic steatohepatitis (NASH), now termed metabolic dysfunction-associated steatohepatitis (MASH). While semaglutide showed MASH resolution in 59% of patients in a phase 2 trial (N=320), the drug does not yet carry an FDA-approved NASH indication. Pioglitazone has the strongest randomized evidence base for NASH resolution among all diabetes drugs, via the PIVENS trial [1].

A practical decision framework for choosing between pioglitazone and GLP-1 agonists weighs three variables: (1) whether the patient has biopsy-confirmed NASH or significant insulin resistance favoring pioglitazone, (2) whether cardiovascular or weight-loss benefit is the primary goal favoring GLP-1 agonists, and (3) whether the patient can afford or access GLP-1 therapy at all. For uninsured patients with insulin resistance and fatty liver disease, pioglitazone at $8 per month is not a consolation prize. It is evidence-based first-choice therapy.

How Pioglitazone Works: Mechanism of Action

Pioglitazone is a synthetic ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear transcription factor expressed most densely in adipose tissue. Binding PPARgamma triggers transcription of genes that regulate fatty acid storage, adipocyte differentiation, and glucose transporter (GLUT4) expression [4].

The downstream effects occur in three tissues. In adipose tissue, pioglitazone promotes differentiation of small, insulin-sensitive adipocytes and shifts lipid storage away from visceral depots toward subcutaneous fat. This redistribution lowers circulating free fatty acids, which are a primary driver of hepatic and muscle insulin resistance. In skeletal muscle, increased GLUT4 translocation improves glucose uptake by 20% to 30% based on hyperinsulinemic-euglycemic clamp studies. In the liver, reduced free fatty acid flux lowers hepatic triglyceride content, gluconeogenesis, and de novo lipogenesis [7].

Pioglitazone also reduces several inflammatory markers. TNF-alpha, IL-6, and C-reactive protein levels decline by 20% to 40% with pioglitazone therapy in published trials [2]. This anti-inflammatory profile may explain part of the cardiovascular benefit observed in IRIS and PROactive, separate from glucose lowering alone.

The onset of full clinical effect takes 8 to 12 weeks because the mechanism depends on gene transcription and adipocyte remodeling rather than acute enzymatic inhibition. Prescribers should counsel patients that A1C improvements will not appear in the first month.

Off-Label Value: Pioglitazone for NASH and MASH

The PIVENS trial remains the benchmark. This NIDDK-sponsored, multicenter RCT (N=247) randomized non-diabetic adults with biopsy-confirmed NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks. Pioglitazone achieved NASH resolution (defined by standardized histologic scoring) in 47% of patients versus 22% on placebo (P=0.001). Vitamin E achieved 36% resolution (P=0.005 vs. placebo). Pioglitazone also reduced fibrosis scores, steatosis, and lobular inflammation [1].

A subsequent meta-analysis by Musso et al. published in JAMA Internal Medicine (8 RCTs, 516 patients) confirmed that thiazolidinediones improved fibrosis by at least one stage in significantly more patients than placebo [10]. The AASLD 2023 Practice Guidance on NAFLD states: "Pioglitazone may be used to treat patients with and without type 2 diabetes mellitus with biopsy-proven NASH" [6]. This recommendation carries a strength rating reflecting the PIVENS and supporting trial data.

No FDA-approved pharmacotherapy for NASH existed until resmetirom (Rezdiffra) received accelerated approval in March 2024. Resmetirom costs approximately $4,000 per month. Pioglitazone, at $8 per month, produces histologically proven NASH resolution at rates that remain competitive with resmetirom's phase 3 data (25% to 30% resolution in MAESTRO-NASH). The cost ratio between these two NASH therapies exceeds 500 to 1.

For hepatologists managing MASH patients who cannot access or afford resmetirom, pioglitazone is the pharmacologic backbone. It is also the only option with long-term (96-week) histologic endpoint data from a large, placebo-controlled trial.

Who Should Consider Pioglitazone Over Newer Agents?

The ideal pioglitazone candidate is a patient with pronounced insulin resistance (elevated fasting insulin, acanthosis nigricans, central adiposity), possibly with co-existing NASH/MASH, who does not have heart failure and is either uninsured or underinsured. This profile describes millions of Americans.

Patients with type 2 diabetes on metformin who need a second agent but cannot afford or tolerate GLP-1 agonists represent the largest potential pioglitazone population. A sulfonylurea (glipizide, glimepiride) is the other cheap add-on option at $4 to $10 per month, but sulfonylureas cause hypoglycemia and weight gain without addressing insulin resistance. Pioglitazone causes weight gain of 2 to 4 kg but rarely causes hypoglycemia when used without insulin or sulfonylureas [4].

Contraindications narrow the candidate pool. Active or history of bladder cancer is a labeled contraindication. The FDA's 2016 updated safety review concluded that pioglitazone use for more than one year may be associated with a small increased bladder cancer risk [9]. NYHA class III/IV heart failure is another absolute contraindication due to fluid retention. Osteoporosis risk is elevated, particularly in postmenopausal women, based on PROactive fracture data showing increased distal extremity fractures [2].

Dr. Kenneth Cusi, Chief of Endocrinology at the University of Florida and lead author of the AASLD NAFLD guidance, has noted: "Pioglitazone is underutilized relative to its evidence base. For the right patient, particularly someone with NASH and insulin resistance, there is no cheaper drug with this level of randomized trial support" [6].

Insurance Coverage and Patient Assistance Programs

Nearly all commercial insurers and Medicare Part D plans cover generic pioglitazone on their formularies, typically at Tier 1 (preferred generic) with copays of $0 to $10. Prior authorization is not required for the generic formulation at most carriers.

Medicaid covers pioglitazone in all 50 states. The drug appears on most state preferred drug lists without step therapy requirements. For dual-eligible patients (Medicare plus Medicaid), out-of-pocket costs are $0 to $4.15 per fill depending on income level and plan structure.

Brand Actos is rarely covered. Takeda discontinued its patient assistance program for Actos after generic entry. No manufacturer copay card exists for the brand product. Patients prescribed brand Actos by name will face full retail pricing above $400 per month at most pharmacies, an unnecessary expense given bioequivalent generic availability.

For patients using pharmacy discount cards, the following approximate monthly costs for pioglitazone 30 mg apply as of mid-2026: Costco $3.50 to $5.00, Walmart $4.00, CVS with GoodRx $6.00 to $9.00, Walgreens with RxSaver $7.00 to $12.00. Mark Cuban's Cost Plus Drugs ships pioglitazone at $5.10 for 30 tablets including shipping.

The practical reality: pioglitazone is so inexpensive that even uninsured patients can afford it. The barrier to its use is not cost but rather clinician awareness of its evidence base and comfort managing the side-effect profile (edema, weight gain, fracture risk) in appropriate candidates.